Results 51 to 60 of about 5,080 (193)

Lecanemab: nueva opción terapéutica en la enfermedad de Alzheimer precoz [PDF]

Introducción: las enfermedades neurodegenerativas continúan siendo un desafío de salud pública a escala mundial. La enfermedad del Alzheimer es la forma más frecuente de estas alteraciones neurodegenerativas y la causa más prevalente de demencia.
Peralta Parra, Paula Leticia
core   +1 more source

Outcomes reported in interventional studies for mild cognitive impairment: a scoping umbrella review to inform core outcome set development

Alzheimer's &Dementia, Volume 22, Issue 9, September 2026.
Abstract There is currently no consensus on the most important treatment outcomes in patients with mild cognitive impairment (MCI). As part of developing a core outcome set for MCI, we conducted a pragmatic scoping umbrella review to summarize outcomes reported in previous studies.
Victoria Grace Gabb, Sam Harding, Tomas Lemke, Sophie Alderman, Natalie Woodward, Julie Clayton, Angus McNair, Winsome Barrett‐Muir, Alan Richardson, Jemima Dooley, Sarah Rudd, Elizabeth Coulthard, Nicholas Turner   +12 more
wiley   +1 more source

Lecanemab and Donanemab in Early Alzheimer’s Disease: A Systematic Review of Clinical, Biomarker, and Safety Outcomes

CHRISMED Journal of Health and Research
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia worldwide. Characterized by amyloid-beta (Aβ) accumulation, tau pathology, and cognitive decline, it has long lacked effective disease-modifying ...
Dharmendra Kumar Gupta, Arunima Chaudhuri   +1 more
doaj   +1 more source

Reply to “CSF Amyloid‐β Risk Stratification in CAA: A Missing Link for Anti‐Amyloid Therapy Safety”

Annals of Neurology, EarlyView.
Philipp Arndt, Stefanie Schreiber
wiley   +1 more source

Operationalizing Alzheimer's disease trials in the era of targeted therapies

Alzheimer's &Dementia, Volume 22, Issue 9, September 2026.
Abstract The therapeutic landscape of Alzheimer's disease (AD) is rapidly evolving with the clinical adoption of anti‐amyloid monoclonal antibodies (mAbs) despite an incomplete understanding of disease mechanisms, progression, and heterogeneity. Designing both observational longitudinal cohorts and clinical trials with novel mAbs in mind is imperative.
Jagan A. Pillai, Suvarna Alladi, Brian S. Appleby, Jared Robert Brosch, Kristian Steen Frederiksen, Douglas Galasko, Oscar L. Lopez, James B. Leverenz, Andrew J. Saykin, Jonathan M. Schott, Sudha Seshadri, Babak Tousi, David A. Wolk   +12 more
wiley   +1 more source

Sex differences in treatment effects of lecanemab and donanemab: A Bayesian reanalysis of CLARITY‐AD and TRAILBLAZER‐ALZ2

Alzheimer’s & Dementia: Translational Research & Clinical Interventions
INTRODUCTION This study investigated evidence for or against a difference in treatment effect between women and men for lecanemab and donanemab. METHODS Data were derived from supplementary analyses of the regulatory studies CLARITY‐AD (lecanemab) and ...
Stefan J. Teipel, Yi Tang, Ara Khachaturian   +2 more
doaj   +1 more source

Enhancing early Alzheimer's disease clinical trials through prognostic score covariate adjustment

Alzheimer's &Dementia, Volume 22, Issue 9, September 2026.
Abstract INTRODUCTION A prognostic score (PS) summarizes a patient's expected disease progression and can increase the statistical efficiency of clinical trials when included as an analysis covariate. METHODS We pooled patient data from observational studies and randomized trials for early Alzheimer's disease (AD) and trained PS candidates to predict ...
Bruno T. Scodari, Roland Brown, Xiaotong Jiang, Changyu Shen, Kyle Ferber, Shuang Wu, Feng Gao, Szofia Bullain, Brian Millen   +8 more
wiley   +1 more source

Long‐term value of lecanemab to individuals and families

Alzheimer’s & Dementia: Translational Research & Clinical Interventions
INTRODUCTION An assessment of the value of lecanemab for patients living with Alzheimer's disease (AD) and their care partners provides them and their health‐care providers important information for deciding treatment initiation.
Bryan Tysinger, Yifan Wei, Hanke Heun‐Johnson, Julie M. Zissimopoulos   +3 more
doaj   +1 more source

Divisions over the regulation of lecanemab

The Lancet
sponsorship: ADSF-24-1284328-C) , Bluefield Project, Cure Alzheimer's Fund, OlavThon Foundation, Erling-Persson Family Foundation, Stiftelsen forGamla Tjanarinnor, Hjarnfonden (FO2022-0270) , EU's Horizon 2020 Research and Innovation Programme under Marie Sk & lstrok;odowska-Curie (86019) , EU Joint Programme-Neurodegenerative Disease Research ...
De Strooper, Bart, Haass, Christian, Hardy, John, Zetterberg, Henrik   +3 more
openaire   +4 more sources

Rethinking tau‐targeted therapy in Alzheimer's disease: Toward a dual biomarker strategy

Alzheimer's &Dementia, Volume 22, Issue 9, September 2026.
Abstract Tau pathology is more closely associated with cognitive deterioration than amyloid burden in symptomatic Alzheimer's disease (AD), yet tau‐targeted trials have often interpreted decreases in soluble phosphorylated tau (p‐tau) as evidence of therapeutic success. Emerging data argue for a more biology‐informed framework.
Charlotte E. Teunissen, Lorenzo Pini, Bruno P. Imbimbo   +2 more
wiley   +1 more source